Pap and HPV tests are vital for diagnosis of cancers and precancer stages in cervix. Mostly these tests are performed together for the patient age group between 21-65 years. As per the international Agency for Research on Cancer, more than 85% of cervical cancer patients are from the developing countries, which demands better efficacy screening and treatment programs for women’s health. Since the cancer progression is slow and may take up to 20 years to develop into an advanced stage, there are many opportunities to stop the disease before it becomes fatal. At present, there are many cities in the emerging market that lack resources for a good laboratory with highly trained cytotechnicians and other specialized staff, which is among the major challenges for good results from Pap testing. With the advancement of HPV tests, the prevention possibility of expansion of cervical cancers increases even in the low resource settings because it is a more affordable and cost-effective strategy, leveraging self-sampling potentially. There are countries, such as Australia and New Zealand, which have effectively taken positive measures related to proper HPV and Pap testing to eradicate cervical cancer. However, the current scenario demands more countries to take better initiatives to roll out the advanced screening tests of HPV and Pap through financial support from the government.

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

5. MARKET SEGMENTATION

6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE

7. MARKET OPPORTUNITIES AND FUTURE TRENDS